denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: educational grants from Agios Pharmaceuticals, Inc.; Astex Pharmaceuticals, Inc.; Bristol Myers Squibb; Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; Taiho Oncology, Inc.; and Takeda Oncology
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Diseases, MDS, MPN, Myeloid Malignancies
Hematology Disease Topics & Pathways:
Diseases, MDS, MPN, Myeloid Malignancies
Friday, December 4, 2020: 7:00 PM-10:00 PM
Chair:
Guillermo Garcia-Manero, MD, The University of Texas MD Anderson Cancer Center
Disclosures:
Garcia-Manero: Novartis: Research Funding; Onconova: Research Funding; Merck: Research Funding; Helsinn Therapeutics: Consultancy, Honoraria, Research Funding; Acceleron Pharmaceuticals: Consultancy, Honoraria; Amphivena Therapeutics: Research Funding; H3 Biomedicine: Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Honoraria, Research Funding; Jazz Pharmaceuticals: Consultancy; Astex Pharmaceuticals: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Celgene: Consultancy, Honoraria, Research Funding.
Speakers:
Ayalew Tefferi, MD, Mayo Clinic
,
Valeria Santini, AOU Careggi-University of Florence
and
Ruben Mesa, MD, UT Health San Antonio Cancer Center
Disclosures:
Santini: Takeda: Consultancy, Honoraria; Menarini: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Acceleron: Consultancy; Takeda: Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Johnson & Johnson: Honoraria. Mesa: Incyte: Research Funding; Genentech: Research Funding; Promedior: Research Funding; LaJolla Pharmaceutical Company: Consultancy; Celgene: Research Funding; CTI BioPharma: Research Funding; Samus Therapeutics: Research Funding; Novartis: Consultancy; Sierra Oncology: Consultancy; Bristol Myers Squibb: Research Funding; AbbVie: Research Funding.
This live program is designed to update physicians on the latest advancements in the clinical management of MDS and MPNs, including current approaches, diagnostic strategies, anemia management, and novel therapies under investigation for these diseases. In addition, this program will use case studies to apply recent findings to real-world case scenarios and will allow participants to reflect on how they might handle each scenario.
See more of: Satellite Symposia